2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Art. -Nr. Produktname CAS. Nr. Reinheit Chemische Struktur
  • HY-109133
    Pecavaptan 1914998-56-3 98%
    Pecavaptan, a chemical probe, is an orally active and dual antagonist of V1a/V2 receptor (Ki=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema.
    Pecavaptan
  • HY-109156
    Pregabalin arenacarbil 1174748-30-1 98%
    Pregabalin arenacarbil is a proagent of Pregabalin.Pregabalin is an analog of gamma-aminobutyric acid (GABA) for the research of post herpetic neuralgia, peripheral diabetic neuropathy,fibromyalgia and epilepsy.
    Pregabalin arenacarbil
  • HY-109514
    Imiglucerase 154248-97-2
    Imiglucerase is a recombinant human glucocerebrosidase that glucosylceramide to glucose and ceramide. Imiglucerase can be used for the study of type 1 (non-neuronopathic) and type 3 (chronic neuronopathic) Gaucher's disease.
    Imiglucerase
  • HY-109692
    GPR120 Agonist 5 1079821-35-4 98%
    GPR120 Agonist 5 (compound 12) is an agonist targeting GPR120 (EC50=1.2 μM). GPR120 Agonist 5 promotes the release of glucagon-like 1 (GLP-1) by binding to the GPR120 receptor, which in turn binds to its receptors on pancreatic beta cells, increasing insulin secretion and thereby lowering blood sugar levels. GPR120 Agonist 5 also helps reduce chronic low-grade inflammation, which plays an important role in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. GPR120 Agonist 5 can be used to investigate the mechanism of action of GPR120 in metabolic and inflammatory diseases.
    GPR120 Agonist 5
  • HY-110005
    Sp-cAMPS triethylamine 93602-66-5 98%
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM.
    Sp-cAMPS triethylamine
  • HY-110020
    rel-O-2050 851320-29-1 98%
    rel-O-2050 (Compound O-2050) is a neutral cannabinoid CB1 receptor antagonist. rel-O-2050 also decreases food intake in mice.
    rel-O-2050
  • HY-110022
    GW1929 hydrochloride 1217466-21-1 98%
    GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential.
    GW1929 hydrochloride
  • HY-110034
    Didesmethylsibutramine hydrochloride 84484-78-6 98%
    Didesmethylsibutramine (BTS 54-505) hydrochloride is the primary amine metabolite of Sibutramine (antidepressant and anti-obesity agent). Didesmethylsibutramine hydrochloride inhibits NMDA-evoked activity. Didesmethylsibutramine hydrochloride is also a reuptake inhibitor. Didesmethylsibutramine hydrochloride induces thermogenesis.
    Didesmethylsibutramine hydrochloride
  • HY-110092
    PSB-1114 tetrasodium 1657025-60-9 98%
    PSB-1114 tetrasodium is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 tetrasodium displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors.
    PSB-1114 tetrasodium
  • HY-110107
    GW438014A 469861-49-2 99.98%
    GW438014A is a potent and selective NPY-Y5 receptor antagonist. GW438014A inhibits food intake and reduces body weight gain in obese rodents.
    GW438014A
  • HY-110134
    S07662 883226-64-0 98%
    S07662 is a human constitutive androstane receptor (hCAR) inhibitor with an IC50 of 0.7 μM. S07662 recruits the corepressor NCoR in cell-based assays and attenuate the expression of CYP2B6 mRNA in human primary hepatocytes induced by phenytoin (HY-B0448) and CITCO (HY-103244).
    S07662
  • HY-110186
    PQ-69 910045-32-8 98%
    PQ-69 is a potent and selective adenosine A1 receptor antagonist with inverse agonist activity. PQ-69 binds to hA1 receptor with a Ki value of 0.96 nM, is 217-fold more selective compared with hA2A receptors (Ki=208 nM) and >1,000-fold selectivity over hA3 receptor (Ki >100 μM). PQ-69 can be used for the research of renal dysfunction.
    PQ-69
  • HY-111049
    GSK8062 943549-47-1 98%
    GSK8062 is a farnesoid X receptor (FXR) agonist with activity that improves compound development parameters. Analog 1c of GSK8062 showed a reduction in weight gain and serum glucose levels.
    GSK8062
  • HY-111068
    KD-3010 934760-92-6 98%
    KD-3010 is a potent, orally active, and selective PPARδ agonist.
    KD-3010
  • HY-111096
    IDN-7314 254750-11-3 98%
    IDN-7314 is a pan-Caspase inhibitor with an IC50 of 0.2-7 nM against all tested Caspases. IDN-7314 abrogates Jo2-induced caspase-3/7 activity. IDN-7314 reduces the procoagulant activity of tissue factor in hepatocytes. IDN-7314 is applicable to research related to chemically induced hepatitis, fulminant liver failure and apoptotic liver injury.
    IDN-7314
  • HY-111131
    RY764 491845-95-5 98%
    RY746 is a selective MC4R agonist, with an EC50 of 10 nM. RY764 effectively inhibits food intake and reduces body weight gain in diet-induced obese (DIO) rat models. RY764 can be used for the study of obesity.
    RY764
  • HY-111141
    AM-3189 916219-50-6 98%
    AM-3189 is an orally active and selective GPR40 agonist with EC50 values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes.
    AM-3189
  • HY-111150
    AMG-222 913978-37-7 98%
    AMG-222 is a dipeptidyl peptidase IV (DPP-IV) inhibitor that exerts its inhibitory effect by tightly and reversibly binding to DPPIV. AMG 222 binds to human plasma proteins in a saturable and concentration-dependent manner, with a binding rate of 80.8% at 1 nM, while the binding rate decreases to 29.4% at concentrations above 100 nM. AMG-222 can be used in research related to diabetes.
    AMG-222
  • HY-111181
    A 56234 90247-09-9 98%
    A 56234 is an orally active benzisoxazole diuretic. A 56234 produces dose-dependent diuresis, sodium and chloride excretion, significantly increases potassium excretion, and also slightly increases calcium, magnesium, and total protein excretion. A 56234 has shown uricosuric effects in animal studies
    A 56234
  • HY-111294
    ASP4000 hydrochloride 851389-35-0 98%
    ASP4000 hydrochloride is a potent, competitive, selective, orally active DPP4 inhibitor with an IC50 value of 2.25 nM against human recombinant DPP4. ASP4000 hydrochloride shows antihyperglycemic activity. ASP4000 hydrochloride can be used in the research of type 2 diabetes.
    ASP4000 hydrochloride
Art. -Nr. Produktname / Synonyms Application Reactivity